We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
- Authors
Norshidah, Harun; Vignesh, Ramachandran; Lai, Ngit Shin
- Abstract
Approximately 100–400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug.
- Subjects
UNITED States. Food &; Drug Administration; DENGUE; DENGUE viruses; DRUG efficacy; VACCINE development; ARBOVIRUS diseases; VACCINES; DISEASE vectors; VACCINE effectiveness
- Publication
Molecules, 2021, Vol 26, Issue 22, p6768
- ISSN
1420-3049
- Publication type
Article
- DOI
10.3390/molecules26226768